SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001104659-22-119870 from INVIVO THERAPEUTICS HOLDINGS CORP. (CIK 0001292519)

INVIVO THERAPEUTICS HOLDINGS CORP. (CIK 0001292519)
Date: Nov. 17, 2022 · CIK: 0001292519 · Accession: 0001104659-22-119870

AI Filing Summary & Sentiment

File numbers found in text: 333-268256

Date
November 17, 2022
Author
Not clearly detected
Form
CORRESP
Company
INVIVO THERAPEUTICS HOLDINGS CORP. (CIK 0001292519)

Letter

InVivo Therapeutics Holdings Corp.

One Kendall Square, Suite B14402

Cambridge, MA 02139

November 17, 2022

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re: InVivo Therapeutics Holdings Corp.

Registration Statement on Form S-1

File No. 333-268256

Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, InVivo Therapeutics Holdings Corp. hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-268256), so that it may become effective at 4:00 p.m. on November 21, 2022, or as soon thereafter as practicable.

[Remainder of Page Intentionally Left Blank]

Very truly yours,
INVIVO THERAPEUTICS HOLDINGS CORP.

Show Raw Text
CORRESP
1
filename1.htm

InVivo Therapeutics Holdings Corp.

One Kendall Square, Suite B14402

Cambridge, MA 02139

November 17, 2022

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

    Re:
    InVivo Therapeutics Holdings Corp.

    Registration Statement on Form S-1

    File No. 333-268256

    Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities
Act of 1933, as amended, InVivo Therapeutics Holdings Corp. hereby requests acceleration of the effective date of its Registration Statement
on Form S-1 (File No. 333-268256), so that it may become effective at 4:00 p.m. on November 21, 2022, or as soon thereafter as practicable.

[Remainder
of Page Intentionally Left Blank]

    Very truly yours,

    INVIVO THERAPEUTICS HOLDINGS CORP.

    By:
    /s/
    Richard Toselli

    Name: Richard Toselli

    Title: President and Chief Executive
    Officer

Signature Page to Acceleration
Request